Cellular cardiomyoplasty (CCM), or introduction of immature cells into terminally injured heart, can mediate repair of chronically injured myocardium. Several different cell types, ranging from embryonic stem cells to autologous skeletal myoblasts, have been successfully propagated within damaged heart and shown to im prove myocardial performance. However, it is unclear if the functional advantages associated with CCM depend upon the use of myogenic cells or if similar results can be seen with other cell types. Thus, we compared indices of regional contractile (systolic) and diastolic myocardial performance following transplan tation of either autologous skeletal myoblasts (Mb) or dermal fibroblasts (Fb) into chronically injured rabbit heart. In vivo left ventricular (LV) pressure (P) and regional segment length (SL) were determined in 15 rabbits by micromanometry and sonomicrometry 1 week following LV cryoinjury (CRYO) and again 3 weeks after autologous skeletal Mb or dermal Fb transplantation. Quantification of systolic performance was based on the linear regression of regional stroke work and end-diastolic (ED) SL. Regional diastolic proper ties were assessed using the curvilinear relationships between LVEDP and strain (e) as well as LVEDP and EDSL. At study termination, cellular engraftment was characterized histologically in a blinded fashion. Indices of diastolic performance were improved following CCM with either Mb or Fb. However, only Mb transplantation improved systolic performance; Fb transfer actually resulted in a significant decline in sys tolic performance. These data suggest that both contractile and noncontractile cells can improve regional material properties or structural integrity of terminally injured heart, as reflected by improvements in dia stolic performance. However, only Mb improved systolic performance in the damaged region, supporting the role of myogenic cells in augmenting contraction. Further studies are needed to define the mechanism by which these effects occur and to evaluate the long-term safety and efficacy of CCM with any cell type.
INTRODUCTION
Ischemia-induced myocardial injury leads to cardiomyocyte death and is a leading cause of adult morbidity and mortality (1) . Because adult cardiomyocytes cannot effectively regenerate to replace injured myocardium (11) , untreated ischemia is often associated with com pensatory left ventricular (LV) hypertrophy and subse quent congestive heart failure (CHF). Although medical management with inotropic agents, digitalis, and ACE inhibitors has significantly improved outcome and slowed disease progression in many patients, progres sion to end-stage disease still occurs. Moreover, these treatments are aimed at improving contractility of the remaining uninjured heart. Surgical revascularization re mains the treatment of choice for ischemic myocardium; however, patients with diffuse ischemic disease or endstage heart failure may not be appropriate candidates for these procedures. In these patients, treatment options proven to improve survival or quality of life are quite limited, prompting continued investigation of alternative treatment strategies.
Recently, cellular cardiomyoplasty (CCM), a tech nique in which immature cells are transplanted into in jured myocardium (25, 34) , has been proposed as a method to restore functional tissue (38) in areas of chronic myocardial ischemia. Several different cell types (5, 7, 9, 28, 34, 35, 38) have been shown to generate viable tissue in a variety of chronic myocardial injury models (6, 7, 28, 38, 42) . Yet, in most CCM studies, myogenic or contractile cells have been employed, including skeletal myoblasts (9, 18, 28, 38) , allogeneic fetal cardiocytes Accepted October 20, 1999 . Address correspondence to Doris A. Taylor, Ph.D., Duke University Medical Center, Box 3345, Durham, NC 27710. Tel: (919) 684-4484; Fax: (919) 684-8907; E-mail: dataylor@duke.edu (21, 23, 37, 42) , allogeneic cardiocytes derived from em bryonic stem cells (17) , and smooth muscle cells (22) .
Few nonmyogenic or noncontractile cell sources have been successfully used, although several groups recently reported preliminary data implying successful engraft ment of fibroblasts or undifferentiated stem cells into chronically injured heart (16, 35) . These recent data sug gest that either contractile or noncontractile cells can en graft and produce viable regions of tissue in previously injured myocardium.
Beyond successful generation of nascent healthy tis sue within injured regions of myocardium, CCM ap pears to alter the structural deterioration, which often accompanies myocardial injury (2, 3, 6, 7, 21, 28) . Partly due to these changes in structural integrity, CCM with myogenic cells, cardiocytes, or skeletal myoblasts has further been associated with improved indices of myo cardial performance both in vitro (21) and in vivo (2, 3, 6, 38) . However, an optimal cell type for use in CCM to improve performance has not been determined.
One significant outstanding issue is whether myogenic (contractile) cells offer an advantage over noncontractile cells in improving myocardial performance. Few, if any, data exist where a direct comparison of the in vivo func tional effects of transplanted myogenic and nonmyo genic cells has been made.
We hypothesized that either myogenic or nonmyo genic cells could favorably influence regional myocar dial geometry or material properties and thus improve diastolic indices of myocardial performance. We further hypothesized that myoblasts, as contractile cells, were likely to yield a greater benefit than noncontractile fibro blasts in that they were additionally likely to augment systolic performance as reflected by myocardial work.
To test this hypothesis, we directly injected autologous skeletal myoblasts or autologous dermal fibroblasts into chronically injured rabbit heart and compared in vivo regional myocardial systolic and diastolic performance 3 weeks postcellular engraftment. 
MATERIALS AND METHODS

In Vitro Myoblasts/Fibroblasts
From a 500-700-mg soleus muscle biopsy, approxi mately 10 7 skeletal myoblasts were mechanically iso lated, expanded, and harvested for transplantation as previously described (39) . Myoblasts were expanded in vitro until less than 20 min before intramyocardial injec tion. At the conclusion of the study, skeletal musclederived cells were identified histologically in cardiac sections by positive antibody staining for myogenin, a skeletal muscle-specific gene product.
Autologous dermal fibroblasts were isolated from an approximately 6-mm 2 biopsy as previously described with slight modifications (29) . Briefly, skin biopsies were incubated overnight in a dispase solution (25 csu/ ml in Ca 2+ /Mg 2+ -free HBSS) and the dermis was me chanically isolated the second day. The dermis was then cut into 1-mm 2 pieces, centrifuged onto culture plates, Finally, cells were pelleted, washed twice in DMEM, and replated in fibroblast growth media until harvest for intracardiac injection the following day.
Physiologic Data Acquisition
Initial physiologic data were recorded 5-7 days after CRYO as previously described (19) . Animals were stud ied under mild sedation (ketamine 30 mg/kg, IM and acepromazine 1 mg/kg, IM). Subcutaneous ultrasonic dimen sion transducers were exposed through a small cutaneous incision under local lidocaine anesthesia (0.8 mg/kg).
At each study, a 2.5 Fr micromanometer (PC500, Millar Instruments, Houston, TX) was placed in the LV cavity, and a 4 Fr Fogarty embolectomy catheter (Model 120804F, Baxter Healthcare Corp., Irvine, CA) was placed in the proximal inferior vena cava as described previously (19) . Data were collected across a range of loading conditions created by inflating the embolectomy balloon.
Ultrasonic dimension transducer pairs were con nected to a sonomicrometer (James W. Davis Consul tant, Inc., Durham, NC), and digitized regional LV mi nor axis dimensions and LV intracavitary pressures were recorded as previously described (19) .
Final physiologic data were recorded in a similar manner 3 weeks after intracardiac injection of either 10 7 autologous skeletal myoblasts or dermal fibroblasts.
Histologic Analysis
At the conclusion of the study, all hearts were har vested and placed in 30% sucrose in phosphate-buffered saline (PBS). After complete infiltration, hearts were cut The cardiac cycle was defined using the first-time de rivative of LV pressure (dP/dt) as detailed previously (14) . Diastole was defined as beginning 15 ms after the first zero crossing of dP/dT following peak negative dP/ dT and ending 15 ms prior to the systolic upstroke of LV intracavity pressure. Beginning-ejection and endejection were placed at peak positive and peak negative dP/dT, respectively. Mean LV pressure was defined as the mean LV intracavitary pressure during ejection.
Regional Systolic Performance
Systolic performance was based on the linear regres sion of SW, determined by integrating P and the change in segment length throughout the cardiac cycle, versus end-diastolic segment length (EDSL) described by eq.
(1) and referred to as the preload recruitable stroke work (PRSW) relationship:
where M w is the slope of the PRSW relationship and reflects regional myocardial contractility, and L w is the Jt-intercept.
Stroke work at a constant EDSL of 1.2 L" mm (SWEDL), a normalized index of regional contractile performance, was additionally determined to quantify systolic function and is determined by:
where L wmax is the maximal x-intercept for a given exper iment. The factor of 1.2 was included to ensure that SWEDL was always positive yet diminished as L w ap proached L wmax (13). 
Regional Diastolic Properties
RESULTS
Histology
All hearts were examined to ensure that a transmural cryoinjury devoid of intact cardiac tissue was achieved ( Fig. 1A, B ). In hearts transplanted with autologous skeletal Mb (Fig. IC, D) , organized foci ( Fig. IC) of myogenin-positive cells (Fig. ID) were seen within the scarred region of myocardium, which appeared to be or ganized into elongated myotubes. Ultrastructural exami nation revealed apposed, single cells connected by inter calated discs and gap junctions similar to that seen previously (38) . Mb engraftment was not uniform in all hearts examined, but with maximal engraftment, Mb oc cupied approximately 75% of the injured area (Fig. IC) .
In contrast, after intracardiac transplantation of Fb, evenly distributed Di-I-positive cells were present throughout the injured region ( Fig. IE, F) . Unlike Mb, Fb did not appear to coalesce and form centralized foci within the scar, nor did they appear to express ultrastruc tural characteristics (intercalated discs and gap junc tions) seen in the transplanted myogenic cells. However, Fb did distribute throughout each infarct and occupy up to 70% of the area. Moreover, the reproducibility of cell distribution from animal to animal was greater than with myoblasts. Ultimately, neither population of engrafted cells extended beyond the borders of the infarcted area into undamaged myocardium.
Systolic Performance
Highly linear preload recruitable stroke work (PRSW) relationships (r 2 > 0.95) indicative of regional systolic performance were obtained for each animal 1
week after CRYO and 3 weeks following cell transplan tation ( Fig. 2A) . As demonstrated in a typical relation ship in Figure 2A , CCM with Mb tended to decrease the x-intercept and significantly increase the slope (A/ w ) of the PRSW relationship. In contrast, after Fb engraft ment, the x-intercept of the PRSW relationship contin ued to increase, and the slope significantly decreased.
As depicted in Figure 2B the difference between the two treatments reaches a sta tistical significance of p < 0.02 (Fig. 2B, C) .
Diastolic Properties
Diastolic properties often reflect regional myocardial geometry, which is known to change after injury; thus, two indices of diastolic function, myocardial strain (e) and stiffness (dP/dL) were calculated for each animal after cryoinjury and again 3 weeks after CCM with au tologous Mb or Fb. Regional diastolic function was evaluated using the nonlinear relationships P-Po vs. e (Fig. 3A) and P -P 0 vs. EDSL (Fig. 4A) . Mean esti mated e at a normalized pressure of 8 mmHg (8) signifi cantly increased (0.06 ±0.01 CRYO vs. 0.10 ±0.01 CCM-Mb, p = 0.04) following autologous skeletal Mb (n = 7) transfer (Fig. 3B) . Mean e 8 also increased in ani mals transplanted with autologous Fb (n = 8) (0.02 ± 0.01 CRYO vs. 0.04 ± 0.01 CCM-Fb, p = 0.05) (Fig.  3C) . Dynamic stiffness at a normalized pressure of 8 mmHg (dP/dLg) significantly decreased (29 ± 7 mmHg/ mm CRYO vs. 14 ± 1.6 CCM-Mb, p = 0.04) (Fig. 4B) , implying improved regional diastolic properties. Simi larly, dynamic stiffness was decreased approximately 50% following Fb transfer (167 ± 52 mmHg/mm CRYO vs. 73 ± 24 CCM-Fb, p = 0.05) (Fig. 4C) .
DISCUSSION
Transplanting cells into injured myocardium has the potential to regenerate functional tissue in previously damaged regions of heart and to augment myocardial function. Contractile autologous skeletal Mb are a reli able source of reserve cells in many individuals, due to their abundance and lack of immunogenicity. Yet, in patients where myoblast numbers may be limited, such as those with myopathy, an alternative autologous cell source is desirable. To determine if Fb could serve as such a source, we directly compared the effects of auto logous skeletal myoblasts and dermal fibroblasts on in vivo myocardial performance.
Fibroblasts were chosen as an alternate cell source for cellular cardiomyoplasty because they are abundant, are easily expanded from a small biopsy specimen, and normally thrive in harsh cellular environments including ischemic myocardium. Furthermore, the role of wound Although transplanted Fb did not improve systolic performance, both Mb and Fb improved regional dia stolic properties. This suggests that by altering regional geometry or structural integrity of the cryoinjured re gion, the presence of any cell might be preferable to acellular, avascular scar. Supporting this are our previ ous observations that diastolic compliance improves fol lowing CCM with Mb even when the level of engraft ment is insufficient to augment systolic performance (2) (3) (4) .
It is conceivable that, in both the previous and the current study, introduction of cells into the injured myo cardial region during the remodeling phase of scar for mation altered diastolic compliance simply by mitigat ing the severity of scar contraction. This could possibly occur by several mechanisms. One is by interference with the conversion of endogenous wound fibroblasts to myofibroblasts either directly (36) or secondary to cyto kine production by the transplanted cells (8, 20, 31) . Sup porting this is the observation that exogenous applica tion of PDGF, a growth factor similar to that found in injured skeletal muscle, inhibits the phenotypic transfor mation of wound fibroblasts to myofibroblasts both in vitro and in vivo (10, 31) . Transmyocardial laser revas cularization has also been shown to stimulate angiogen esis and growth factors, which could also theoretically affect myocardial diastolic performance (24) . A second mechanism by which CCM could alter wound contrac tion is by providing cells that lack the proper number Taken together, these data further the preliminary findings of our laboratory (16) as well as the reported data of Sakai et al. (35) , which show myogenic cells improve systolic performance to a greater degree than noncontractile fibroblasts. However, the data further show that both cell types positively impact regional dia stolic properties of damaged heart, and thus may be of benefit in diastolic disease. Further investigations of the mechanism through which this occurs and of the longterm effects of each cell type on performance appear warranted.
Overall, future studies with myoblasts must concen trate on defining the biology by which engraftment leads to an improvement in contractile performance. These should include studies aimed at improving reproducibil ity of engraftment, and at mapping the electrical synchronicity of transplanted cells. Yet, the current study suggests several other areas of future investigation. For example, taking advantage of the vigorous migration and widespread distribution of fibroblasts, Fb could be engineered to release angiogenic peptides throughout in jured heart to improve the viability of either hibernating myocardium or cotransplanted myoblasts. Alternatively, myoblasts could be engineered to locally release a factor that induces apoptosis of endogenous wound fibroblasts prior to their conversion to myofibroblasts and theoreti cally prevent scar contraction altogether. This type of intervention could potentially preserve myocardial ge ometry and allow transplanted myoblasts to grow be yond the centralized focus that they now form. Finally, further investigation is needed to determine if cell distri bution, cell number, and cell cytokine or growth factor secretion can be altered to improve myocardial function to an even greater degree.
In summary, these studies demonstrate that trans planting viable cells into injured myocardium may be of functional benefit even when systolic performance is not improved, and further suggest that cell type may only be critical when considering systolic outcome.
